Rituximab shows promise for IgG4-related pancreaticobiliary disease

Rituximab (RTX) shows promise as an effective treatment for maintaining remission in IgG4-related pancreaticobiliary disease (IgG4-PBD), with a relatively low risk of side effects, according to a study.

In their systematic review, researchers analyzed data from 12 studies, comprising 257 patients, to assess the efficacy and safety of RTX. Using standard meta-analysis techniques, they reviewed remission and relapse rates, partial remission, and side effects. Results showed a complete remission rate of 68% and a relapse rate of 23%. Adverse events were recorded in 21% of patients, with mild infusion reactions and infections noted at 12% and 14%, respectively.

Reference
Loganathan P, Siby N, Mohan BP, et al. Efficacy of Rituximab in Autoimmune-Mediated IgG4 Pancreaticobiliary Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2024;doi: 10.1097/MCG.0000000000002078. Epub ahead of print. PMID: 39331507.